Department of General, Transplant and Liver Surgery, Medical University of Warsaw, Warsaw, Poland.
Hepatology and Internal Medicine Unit, Department of General, Transplant and Liver Surgery, Medical University of Warsaw, Warsaw, Poland.
Ann Surg. 2020 Jun;271(6):1124-1131. doi: 10.1097/SLA.0000000000003176.
To assess the potential influence of replacing Milan criteria with simple risk scores on outcomes of hepatocellular carcinoma (HCC) patients undergoing liver transplantation.
Several risk scores combining morphological and biological features were recently proposed for precise selection of HCC patients for transplantation.
This retrospective study included 282 HCC liver transplant recipients. Recurrence-free survival (RFS), the primary outcome measure, was evaluated according to Metroticket 2.0 model and French AFP model with Milan criteria serving as benchmark.
Patients were well stratified with respect to RFS by Milan criteria, Metroticket 2.0 criteria, and AFP model cut-off ≤2 points (all P < 0.001) with c-statistics of 0.680, 0.695, and 0.681, respectively. Neither Metroticket 2.0 criteria (0.014, Z = 0.023; P = 0.509) nor AFP model (-0.014, Z = -0.021; P = 0.492) provided significant net reclassification improvement. Both patients within the Metroticket 2.0 criteria and AFP model ≤2 points exhibited heterogeneous recurrence risk, dependent upon alpha-fetoprotein (P = 0.026) and tumor number (P = 0.024), respectively. RFS of patients beyond Milan but within Metroticket 2.0 criteria (75.3%) or with AFP model ≤2 points (74.1%) was inferior to that observed for patients within Milan criteria (87.1%; P = 0.067 and P = 0.045, respectively). Corresponding microvascular invasion rates were 37.2% and 50.0%, compared with 13.6% in patients within Milan criteria (both P < 0.001). Moreover, Milan-out status was associated with significantly higher recurrence risk in subgroups within Metroticket 2.0 criteria (P = 0.021) or AFP model ≤2 points (P = 0.014).
Utilization of simple risk scores for liver transplant eligibility assessment leads to selection of patients at higher risk of posttransplant HCC recurrence.
评估用简单的风险评分替代米兰标准对接受肝移植的肝细胞癌(HCC)患者结局的潜在影响。
最近提出了几种结合形态学和生物学特征的风险评分,用于对 HCC 患者进行精确选择以进行移植。
这项回顾性研究纳入了 282 例 HCC 肝移植受者。无复发生存(RFS)是主要的终点指标,根据 Metroticket 2.0 模型和 AFP 模型进行评估,以米兰标准作为基准。
根据米兰标准、Metroticket 2.0 标准和 AFP 模型截断值≤2 分(所有 P<0.001),患者的 RFS 得到很好的分层,其 C 统计量分别为 0.680、0.695 和 0.681。Metroticket 2.0 标准(0.014,Z=0.023;P=0.509)和 AFP 模型(-0.014,Z=-0.021;P=0.492)均未提供显著的净重新分类改善。Metroticket 2.0 标准内的患者和 AFP 模型≤2 分的患者的复发风险存在异质性,取决于甲胎蛋白(P=0.026)和肿瘤数量(P=0.024)。米兰标准之外但 Metroticket 2.0 标准内(75.3%)或 AFP 模型≤2 分(74.1%)的患者的 RFS 低于米兰标准内的患者(87.1%;P=0.067 和 P=0.045)。相应的微血管侵犯率分别为 37.2%和 50.0%,而米兰标准内的患者为 13.6%(均 P<0.001)。此外,米兰标准外的状态与 Metroticket 2.0 标准内的亚组(P=0.021)或 AFP 模型≤2 分的亚组(P=0.014)相比,具有更高的 HCC 复发风险。
使用简单的风险评分来评估肝移植的资格会导致选择移植后 HCC 复发风险更高的患者。